Literature DB >> 23392356

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.

C Albers, H Leischner, M Verbeek, C Yu, A L Illert, C Peschel, N von Bubnoff, J Duyster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23392356     DOI： 10.1038/leu.2013.14

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  28 in total

1.  Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Authors:  Weiguo Zhang; Chen Gao; Marina Konopleva; Ye Chen; Rodrigo O Jacamo; Gautam Borthakur; Jorge E Cortes; Farhad Ravandi; Abhijit Ramachandran; Michael Andreeff
Journal:  Clin Cancer Res       Date:  2014-03-11       Impact factor: 12.531

2.  Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.

Authors:  Catherine C Smith; Amy Paguirigan; Grace R Jeschke; Kimberly C Lin; Evan Massi; Theodore Tarver; Chen-Shan Chin; Saurabh Asthana; Adam Olshen; Kevin J Travers; Susana Wang; Mark J Levis; Alexander E Perl; Jerald P Radich; Neil P Shah
Journal:  Blood       Date:  2017-05-10       Impact factor: 22.113

Review 3.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

4.  MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.

Authors:  B Xu; Y Zhao; X Wang; P Gong; W Ge
Journal:  Leukemia       Date:  2016-10-24       Impact factor: 11.528

5.  Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Authors:  Ellen Weisberg; Chengcheng Meng; Abigail E Case; Martin Sattler; Hong L Tiv; Prafulla C Gokhale; Sara J Buhrlage; Xiaoxi Liu; Jing Yang; Jinhua Wang; Nathanael Gray; Richard M Stone; Sophia Adamia; Patrice Dubreuil; Sebastien Letard; James D Griffin
Journal:  Br J Haematol       Date:  2019-07-15       Impact factor: 6.998

Review 6.  FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Authors:  Michael R Grunwald; Mark J Levis
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

7.  Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Authors:  Sharyn D Baker; Eric I Zimmerman; Yong-Dong Wang; Shelley Orwick; Douglas S Zatechka; Jassada Buaboonnam; Geoffrey A Neale; Scott R Olsen; Eric J Enemark; Sheila Shurtleff; Jeffrey E Rubnitz; Charles G Mullighan; Hiroto Inaba
Journal:  Clin Cancer Res       Date:  2013-08-22       Impact factor: 12.531

8.  Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Authors:  Theodore C Tarver; Jason E Hill; Leena Rahmat; Alexander E Perl; Erkut Bahceci; Kenichi Mori; Catherine C Smith
Journal:  Blood Adv       Date:  2020-02-11

Review 9.  Emerging therapeutic drugs for AML.

Authors:  Eytan M Stein; Martin S Tallman
Journal:  Blood       Date:  2015-12-10       Impact factor: 22.113

10.  The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.

Authors:  Weiguo Zhang; Gautam Borthakur; Chen Gao; Ye Chen; Hong Mu; Vivian R Ruvolo; Kenichi Nomoto; Nanding Zhao; Marina Konopleva; Michael Andreeff
Journal:  Cancer Res       Date:  2016-01-28       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.